Navigation Links
AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
Date:6/19/2012

esign of its future clinical trials. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "will," "may," "potential," "anticipated," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with the timing and success of preclinical studies and clinical trials and the potential problems that may arise in the research and development and approval process, market competition, Rigel's need for additional capital, risks associated with Rigel's corporate partnerships and collaborations, including risks that if conflicts arise between Rigel's and its corporate partners, the clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated, as well as other risks detailed from time to time in Rigel's reports with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Rigel Contacts:
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.com

AstraZeneca Media Enquiries:
Andrea Conners, +44 (0)20 7604 8221 On-site at BIO
Chris Sampson, +32 47
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
2. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
3. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
4. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
5. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
6. ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
9. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
10. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
11. HistoRx Licenses Melanoma Assay from Yale University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... announced today that it will release its full financial results ... on Thursday, March 12 th after market close, followed ... its financial results and business outlook. Participants should ... (412) 542-4135 (International) and request the InspireMD call. A live ...
(Date:3/6/2015)... , March 6, 2015 BioSpecifics Technologies ... developing first in class collagenase-based products marketed as XIAFLEX ... U.S. and XIAPEX ®  in the EU, announced today ... audio webcast at 8:30 a.m. ET on Friday, March ... year 2014 financial results and provide a corporate update. ...
(Date:3/6/2015)... 2015 Die ... der Assistance Publique - Hôpitaux de ... eine französische, gemeinschaftliche, randomisierte Kontrollstudie für die ... Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom ... Sorafenib behandelt wurden. Die Ergebnisse werden für ...
(Date:3/5/2015)... St. Paul, Minn. (PRWEB) March 05, 2015 ... meet in Pasadena this summer at the Annual Meeting ... program are starting to be released online now at ... just been announced for the meeting, to be held ... includes newly announced Special Sessions, Field Trips, Workshops, and ...
Breaking Biology Technology:InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... March 13 Varian Medical Systems (NYSE: VAR ... the non-destructive testing market at the upcoming ASNT Research Symposium ... Millennium Hotel in St. Louis, MO.The company will exhibit a ... , ...
... Technology (TU/e) have for the first time made ... formation. They used the world,s most advanced electron ... that are at the heart of the process. ... and shell formation. For industrial applications, they promise ...
... Call on Friday, March 13, 2009 at 8:30am ... Inc. (Nasdaq: KERX ), a biopharmaceutical ... of medically important, novel pharmaceutical products for the ... cancer (the "Company"), today announced its results for ...
Cached Biology Technology:Varian Medical Systems to Exhibit X-ray and CT Technologies for Non-Destructive Testing at the Upcoming ASNT 18th Annual Spring Conference 2First high-resolution images of bone, tooth and shell formation 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 6
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:2/25/2015)... ROCK, Ark. , Feb. 25, 2015 /PRNewswire/ ... software and billing in the Health and Fitness ... as well as to MYiCLUBonline.  The latest upgrade ... and the inclusion of cardless check-in via Identity ... for the first time through interactive displays at ...
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... University of Guelph researchers has proven up to 88 ... to a new U of G study. The ... Research International . It,s a crucial finding because ... poses economic, health, legal and environmental implications, says study ...
... New Rochelle, NY, September 19, 2012-- Researchers have successfully ... from mice that can be grown in large quantities ... develop into many different cell types needed throughout the ... cell biology and human development and disease is described ...
... KNOXVILLEShoppers particularly women who take the time ... don,t. These findings are from a recently released ... Tennessee professor in the Institute of Agriculture,s Department of ... the University of Santiago de Compostela in Spain, the ...
Cached Biology News:Study: DNA barcoding can ID natural health products 2
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... recombinant human protein produced in E. coli and ... A type enzymes. The mode of inhibition ... a 1:1 ratio. The enzyme has been shown ... cell types. Addition of the ribonuclease inhibitor has ...
Biology Products: